Piaserico, Stefano http://orcid.org/0000-0002-1091-4733
Conti, Andrea http://orcid.org/0000-0003-4848-3817
Messina, Francesco http://orcid.org/0000-0002-7959-5881
Meneguzzo, Alberto http://orcid.org/0000-0003-4862-187X
Odorici, Giulia http://orcid.org/0000-0002-5910-8994
Bellinato, Francesco http://orcid.org/0000-0002-6163-6921
Gisondi, Paolo http://orcid.org/0000-0002-1777-9001
Article History
Accepted: 30 April 2021
First Online: 11 May 2021
Declarations
:
: No funding was needed for this study.
: Stefano Piaserico has been a consultant and/or speaker for Abbvie, Almirall, Celgene, Janssen, Leo-pharma, Eli Lilly, Novartis, Sandoz, UCB; Andrea Conti has been a consultant and/or speaker for Abbvie, Janssen, Eli Lilly, Novartis, Pfizer and UCB; Francesco Messina has no conflict of interest; Alberto Meneguzzo has no conflict of interest; Giulia Odorici has no conflict of interest; Francesco Bellinato has no conflict of interest; Paolo Gisondi has been a consultant and/or speaker for Abbvie, Almirall, Celgene, Janssen, Leo-pharma, Eli Lilly, Novartis, Pfizer, Sandoz, UCB.
: SP, AC and PG designed the study, wrote the article and revised it critically; FM, AM, GO and FB collected the data and participated in the writing of the article and its revision.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.